LP
EWTX icon

Longaeva Partners’s Edgewise Therapeutics EWTX Stock Holding History

Longaeva Partners’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$763K Sell
18,790
-18,141
-49% -$625K 0.02% 304
2026
Q1 		$1.16M Buy
+36,931
New +$1.06M 0.04% 168

Other funds holding EWTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Longaeva Partners's EWTX Position: Q2 2026 in Review

Longaeva Partners reduced its Edgewise Therapeutics (EWTX) stake by 49% in Q2 2026, selling an estimated $625K and leaving 18,790 shares worth $763K. The position accounts for 0.02% of the portfolio, ranked #304.

Longaeva Partners first reported a position in EWTX in Q1 2026 and has held it in 2 quarters since. The position peaked at $1.16M in Q1 2026. 226 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • Longaeva Partners held 18,790 shares of Edgewise Therapeutics worth $763K as of Q2 2026.
  • Longaeva Partners sold 18,141 Edgewise Therapeutics shares in Q2 2026, an estimated $625K.
  • Edgewise Therapeutics made up 0.02% of Longaeva Partners's portfolio in Q2 2026, its #304 holding.
  • Longaeva Partners first reported a position in Edgewise Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Longaeva Partners's Edgewise Therapeutics position peaked at $1.16M in Q1 2026.
  • 226 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on Longaeva Partners's 13F filing for Q2 2026, filed 14 Aug 2026.